<DOC>
	<DOCNO>NCT00449904</DOCNO>
	<brief_summary>This open-label , single-arm clinical study investigate long-term safety ALTU-135 treatment patient cystic fibrosis ( CF ) -related exocrine pancreatic insufficiency ( PI ) .</brief_summary>
	<brief_title>Open-Label Phase III Long-Term Safety Trial Liprotamase</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<criteria>Inclusion Criteria Females childbearing potential must willing use birth control Diagnosis CF base upon follow criterion : Two clinical feature consistent CF ; either A genotype two identifiable mutation consistent CF , Sweat chloride &gt; 60 milliequivalent per liter ( mEq/L ) quantitative pilocarpine iontophoresis . Clinically stable evidence acute upper low respiratory tract infection Exocrine pancreatic insufficiency ( PI ) determine fecal elastase &lt; 100 microgram per gram ( µg/g ) measure Screening Able take pancreatic enzyme supplementation form capsule Able perform test procedure require study , judge Investigator Age &lt; 7 year Pregnancy , breastfeed childbearing potential willing use birth control Participation investigational study drug , biologic , device currently approve marketing within 30 day prior Screening History fibrosing colonopathy History liver transplant , lung transplant significant surgical resection bowel Any chronic diarrheal illness unrelated PI Abnormal liver function ( except patient Gilbert Syndrome ) Signs and/or symptom liver cirrhosis portal hypertension ( e.g. , splenomegaly , ascites , esophageal varix ) , document liver disease unrelated CF Unable discontinue enteral tube feeding study Any condition Investigator believe would interfere intent study would make participation best interest patient Baseline coefficient fat absorption ( CFA ) ≥ 93 % Phase III efficacy study Patient unlikely complete study , determine Investigator</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Cystic fibrosis-related exocrine pancreatic insufficiency</keyword>
</DOC>